MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Начало・Списък с акции・Cogent Biosciences Inc

Cogent Biosciences Inc

Затворен

35.32 -0.11

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

34.96

Максимум

35.45

Ключови измерители
By Trading Economics
Приходи	-22M -102M
Служители	258
EBITDA	-30M -109M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+49.25% upside

Дивиденти
By Dow Jones
Следващи печалби	5.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	137M 5.7B
Предишно отваряне	35.43
Предишно затваряне	35.32

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

4.88 / 5.87 Подкрепа & съпротива

Cogent Biosciences Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.04.2026 г., 04:27 ч. UTC

Значими събития в новините

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

3.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

3.04.2026 г., 18:30 ч. UTC

Значими събития в новините

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

3.04.2026 г., 18:14 ч. UTC

Пазарно говорене

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

3.04.2026 г., 17:50 ч. UTC

Пазарно говорене

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

3.04.2026 г., 17:44 ч. UTC

Придобивния, сливания и поглъщания

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

3.04.2026 г., 16:50 ч. UTC

Значими събития в новините

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

3.04.2026 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

3.04.2026 г., 16:12 ч. UTC

Печалби

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

3.04.2026 г., 15:56 ч. UTC

Пазарно говорене

Значими събития в новините

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

3.04.2026 г., 15:56 ч. UTC

Пазарно говорене

Значими събития в новините

Global Equities Roundup: Market Talk

3.04.2026 г., 15:56 ч. UTC

Пазарно говорене

Значими събития в новините

Global Forex and Fixed Income Roundup: Market Talk

3.04.2026 г., 15:20 ч. UTC

Значими събития в новините

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

3.04.2026 г., 15:08 ч. UTC

Придобивния, сливания и поглъщания

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

3.04.2026 г., 14:11 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

3.04.2026 г., 12:56 ч. UTC

Пазарно говорене

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

3.04.2026 г., 08:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

3.04.2026 г., 08:01 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

3.04.2026 г., 08:01 ч. UTC

Пазарно говорене

Meituan's Profitability Likely to Improve This Year -- Market Talk

3.04.2026 г., 07:45 ч. UTC

Пазарно говорене

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

3.04.2026 г., 06:17 ч. UTC

Пазарно говорене

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

3.04.2026 г., 06:17 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

3.04.2026 г., 04:33 ч. UTC

Пазарно говорене

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

3.04.2026 г., 04:33 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

3.04.2026 г., 04:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

3.04.2026 г., 04:01 ч. UTC

Пазарно говорене

Posco Holdings 1Q Earnings Could Fall Short of Expectations -- Market Talk

3.04.2026 г., 02:01 ч. UTC

Пазарно говорене

India Consumer-Staple Companies Likely to Post Broadly Steady 4Q Results -- Market Talk

3.04.2026 г., 01:59 ч. UTC

Пазарно говорене

Sea's Shopee E-Commerce Platform Likely in Reinvestment Phase -- Market Talk

3.04.2026 г., 01:44 ч. UTC

Пазарно говорене

Samsung Likely to Report Record Quarterly Earnings in 2026 -- Market Talk

3.04.2026 г., 01:22 ч. UTC

Пазарно говорене

Dollar Could Hit 160 Yen in Thin Holiday Trading -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Cogent Biosciences Inc Прогноза

Ценова цел

By TipRanks

49.25% нагоре

12-месечна прогноза

Среден 52.55 USD 49.25%

Висок 64 USD

Нисък 35 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Cogent Biosciences Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

Купи

Задържане

Продай

Според 12 анализатори, дали борсови рейтинги на Cogent Biosciences Inc през последните 3 месеца.

Техническа оценка

By Trading Central

4.88 / 5.87Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.